Europe's highest court has issued a landmark ruling on the law governing supplementary protection certificates in the EU.
Europe’s highest court has issued a landmark ruling on the law governing supplementary protection certificates (SPCs) in the EU.
SPCs extend the period of monopoly for patentees who experience delays in marketing their patented products owing to the need to obtain regulatory approval. They apply only to patents covering human or veterinary medicines, or plant protection products.
National patent offices have previously granted SPCs only to the first product containing a particular active ingredient that regulators have approved. The term of the combined patent and SPC protection has been capped at 15 years (15 years 6 months in some cases).
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on email@example.com.
CJEU, SPCs, EU, Neurim, Circadin